Intuitive Surgical stock stabilizes as Q2 2026 growth and guidance reset sink in

Intuitive Surgical stock is trading around the upper end of its recent range as investors weigh strong Q2 2026 growth against more cautious procedure guidance and a sizable upside to Wall Street price targets.

Intuitive Surgical stock (ISIN US46120E6023) is trading around USD 369.25, leaving the medical technology group’s shares roughly 30 percent below their 12-month high as of September 1, 2026, according to market data compiled from Barchart and MarketBeat.

Q2 2026 figures show double-digit growth

The latest quarterly report for Q2 2026 confirmed that Intuitive Surgical is still expanding at a double-digit pace. According to analyst data summarized by Yahoo Finance, revenue for the second quarter of fiscal 2026 reached USD 2.89 billion, while earnings came in at USD 818.1 million, implying a profit margin of 28.29 percent for the period ended June 30, 2026.

The Q2 2026 earnings release cycle also showed that Intuitive Surgical has been beating expectations. A recent overview reported non-GAAP EPS of USD 2.80 for Q2 2026 against a consensus estimate of USD 2.48, meaning the company outperformed analyst forecasts by USD 0.32 per share, while revenue of USD 2.89 billion came in above expectations of USD 2.83 billion. For investors, the combination of a solid margin profile and a clear beat on both EPS and revenue is an important support for the stock’s long-term story.

Procedure growth slows, but guidance remains positive

Behind the headline figures, the pace of procedure growth has come into sharper focus. As of the second quarter of 2026, Intuitive Surgical guided for worldwide da Vinci procedure growth in full year 2026 of approximately 13 to 15 percent, compared with 18 percent in 2025, according to an earnings summary based on SEC filings. That shift represents a step down of 3 to 5 percentage points versus the prior year, and has contributed to a more cautious tone among some investors.

At the same time, operational metrics remain robust. A recent analysis of Intuitive Surgical’s second quarter noted that worldwide procedure volume rose 16 percent year over year and overall revenue grew 19 percent in Q2 2026. Within that revenue mix, instruments and accessories generated around USD 1.7 billion, while system placements added approximately USD 685 million, highlighting the balance between recurring and capital revenue streams.

System placements also continued to grow. In Q2 2026, Intuitive Surgical placed 468 da Vinci systems, up from 395 systems in the same quarter a year earlier, bringing the global installed base to 11,710 systems as of June 30, 2026. That represents a 12 percent increase in installed systems over the prior year and underscores the long runway for additional procedure volumes over time.

Analyst consensus and valuation context

Despite the stock’s drawdown, the analyst community remains broadly constructive. Data from MarketBeat show that Intuitive Surgical currently carries an average rating of “Moderate Buy” and a consensus 12-month price target of USD 508.68, compared with a reported spot price of USD 369.25. This implies potential upside of around 38 percent if the stock were to reach the consensus target.

Estimates compiled by Yahoo Finance point to continued growth in the coming quarters. For the current quarter ending September 2026, the average revenue estimate stands at USD 2.91 billion, with projections rising to USD 3.22 billion for the December 2026 quarter. On a full-year basis, analysts expect 2026 revenue of about USD 11.77 billion, up from USD 10.06 billion in 2025, implying forecast top-line growth of roughly 17 percent year over year. For 2027, consensus revenue estimates increase further to approximately USD 13.25 billion.

On the earnings side, analyst forecasts show non-GAAP EPS trajectories that build on recent quarterly results. Q4 2025 EPS was reported at USD 2.53 versus a consensus estimate of USD 2.27, while Q1 2026 and Q2 2026 recorded EPS of USD 2.50 and USD 2.80 respectively, confirming that the company has been consistently delivering results ahead of expectations across multiple quarters.

Robotic surgery adoption and competitive landscape

Intuitive Surgical’s performance in Q2 2026 has to be viewed against the broader backdrop of robotic-assisted surgery adoption. The company’s da Vinci systems are increasingly being installed in hospitals and surgical centers worldwide, with recent examples including a Lakewood Ranch Medical Center announcement that it is expanding its robotic surgery program by adding a da Vinci 5 system. Publicly available estimates put the cost of a single da Vinci 5 system between USD 1.8 million and USD 2.5 million, illustrating the scale of capital investment required for hospitals entering or upgrading in this space.

The company also faces growing competition, particularly from peers such as Medtronic, which is investing heavily to build out its own robotic surgery platform. A recent report highlighted that Medtronic committed another USD 700 million to surgical robots, underlining how attractive the segment has become for large medtech groups. For investors in Intuitive Surgical stock, this competitive dynamic matters because it can influence system pricing, placement rates and long-term margin profiles.

Nonetheless, Intuitive Surgical’s installed base of 11,710 da Vinci systems as of June 30, 2026 gives it a significant scale advantage. Each system drives recurring revenue from instruments and accessories, and higher utilization over time supports procedure-based growth even when new system placements fluctuate. The 16 percent year-over-year increase in worldwide procedure volume in the second quarter shows that the underlying demand for minimally invasive robotic surgery remains strong.

Representative product: da Vinci 5 system

A central pillar of Intuitive Surgical’s business model is the da Vinci line of robotic-assisted surgical systems, with the da Vinci 5 representing the latest generation. The platform is designed to enhance surgeons’ precision and control during minimally invasive procedures, using advanced instrumentation, imaging and motion control technology. Hospitals that invest in da Vinci 5 systems typically aim to expand their range of robotic procedures, from urologic and gynecologic surgeries to general and thoracic operations.

While Intuitive Surgical does not routinely disclose individual system pricing in detail, market estimates for the da Vinci 5 system place the acquisition cost in the USD 1.8 million to USD 2.5 million range, depending on configuration and options. For the company, each installed system opens the door to ongoing sales of instruments and accessories, service contracts and, in some cases, training and support services, which together form a recurring revenue stream that complements the upfront system sale.

Stock level and investor perspective

According to Barchart data, Intuitive Surgical stock closed at USD 369.25 on September 1, 2026 on the NASDAQ, down 2.02 percent from the previous session. MarketBeat’s latest overview places the 12-month trading range between a low of USD 328.57 and a high of USD 603.88, with a market capitalization of around USD 133.14 billion at a price of USD 376.86 as of September 1, 2026. That means the current share price is closer to the lower end of the 12-month band than to the prior peak, a positioning that reflects the drawdown of more than 30 percent from early-2026 levels cited in recent commentary.

Key data for Intuitive Surgical stock

• Company: Intuitive Surgical Inc.
• ISIN: US46120E6023
• Ticker: ISRG
• Trading venue: NASDAQ
• Price (as of September 1, 2026): 369.25 USD
• Market capitalization: 133.14 billion USD (as of September 1, 2026)
• Sector / Industry: Health Care / Medical Instruments
• Index membership: S&P 500